Acrivon Therapeutics (ACRV) vs Cognition Therapeutics (CGTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Acrivon Therapeutics (ACRV) has outperformed Cognition Therapeutics (CGTX) over the past year, losing 0.5% versus a loss of 49.1%. Cognition Therapeutics is the larger company by market cap ($85.1 million vs $80.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACRV | CGTX |
|---|---|---|
| Share price | $1.87 | $0.8952 |
| Market cap | $80.14M | $85.13M |
| 1-day change | -0.53% | -4.42% |
| YTD return | -22.41% | -33.69% |
| 1-year return | -0.53% | -49.14% |
| 5-year return | — | -92.48% |
| EPS (TTM) | $-1.88 | $-0.17 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.56 | $2.05 |
| 52-week low | $1.27 | $0.55 |
| Distance from 52-week high | -47.47% | -56.33% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +514.97% | +271.98% |
| Average volume | 356.18K | 534.62K |
| Shares outstanding | 42.85M | 95.09M |
| Employees | 74 | 14 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACRV has outperformed CGTX by 48.6 percentage points over the past year.
About Acrivon Therapeutics
ACRV stock →Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.
Health Care · Biotechnology: Pharmaceutical Preparations · 74 employees
About Cognition Therapeutics
CGTX stock →Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 14 employees
ACRV vs CGTX FAQ
Which is bigger, Acrivon Therapeutics or Cognition Therapeutics?
Cognition Therapeutics (CGTX) is larger, with a market capitalization of $85.13M compared with $80.14M for Acrivon Therapeutics (ACRV).
Which stock has performed better over the past year, ACRV or CGTX?
ACRV returned -0.53% over the past 12 months, compared with -49.14% for CGTX (price return, excluding dividends). Past performance does not predict future results.
Are Acrivon Therapeutics and Cognition Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Acrivon Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Cognition Therapeutics.